Highlights CureVac N.V. Deutsche Boerse AG

Equities

Market Closed - Deutsche Boerse AG Other stock markets 20:19:05 05/07/2024 BST			After market 21:00:01
3.004 ^EUR	-0.86%		3.02	+0.53%

07-03	Health Stocks Slip in Risk-On Trade -- Health Care Roundup	DJ
07-03	Sector Update: Health Care Stocks Fall in Afternoon Trading	MT

Sector Update: Health Care Stocks Fall in Afternoon Trading	07-03	MT
Sector Update: Health Care	07-03	MT
European Equities Close Higher in Wednesday Trading; Euro Area Growth Slows to 3-Month Low	07-03	MT
Sector Update: Health Care Stocks Steady Pre-Bell Wednesday	07-03	MT
Sector Update: Health Care	07-03	MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Ahead of Economic Data Deluge	07-03	MT
GSK to Buy COVID-19, Flu Vaccine Rights From CureVac for $1.56 Billion	07-03	MT
Top Premarket Gainers	07-03	MT
GSK to Buy CureVac's Covid-19, Flu Vaccine Rights for Up to $1.56 Billion -- 2nd Update	07-03	DJ
GSK to Buy CureVac's Covid-19, Flu Vaccine Rights in Up to $1.56 Billion Deal -- Update	07-03	DJ
CureVac Enters Into New Licensing Agreement With GSK; to Implement 'Significant' Restructuring; Shares Rise Pre-Bell	07-03	MT
GSK, CureVac Expand Licensing Agreement	07-03	DJ
Keywords Studios agrees takeover by EQT	07-03	AN
GSK and CureVac to Restructure Collaboration into New Licensing Agreement	07-03	CI
GSK Signs New Licensing Deal With CureVac for Influenza, Covid-19 Vaccines	07-03	MT
Gsk PLC - Gsk And Curevac Collaboration Restructured	07-03	RE
CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate	05-28	MT
CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK	05-28	CI
CureVac N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-23	CI
CUREVAC : Significant cash drain in the Q1	05-23

No results for this search

CUREVAC : Significant cash drain in the Q1

May 23, 2024 at 08:49 pm